Preclinical efficacy and safety of KCNH2-G628S gene therapy for postoperative atrial fibrillation.

Liu, Zhao; Hutt, Julie A; Rajeshkumar, Barur; Azuma, Yoshihiro; Duan, Kailai L; Donahue, J Kevin

Liu, Zhao; Hutt, Julie A; Rajeshkumar, Barur; Azuma, Yoshihiro; Duan, Kailai L; Donahue, J Kevin.

Afiliação

Liu Z; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio.
Hutt JA; The Lovelace Respiratory Research Institute, Albuquerque, NM.
Rajeshkumar B; Department of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Mass.
Azuma Y; Department of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Mass.
Duan KL; Department of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Mass.
Donahue JK; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio; Department of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Mass. Electronic address: donahuelab@gmail.com.

J Thorac Cardiovasc Surg ; 154(5): 1644-1651.e8, 2017 11.

Article em En | MEDLINE | ID: mdl-28676183

Assuntos

Fibrilação Atrial; Procedimentos Cirúrgicos Cardíacos; Animais; Canal de Potássio ERG1; Terapia Genética; Átrios do Coração; Humanos; Período Pós-Operatório; Suínos

Palavras-chave

atrial fibrillation; gene therapy; operative complications; potassium channel

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Procedimentos Cirúrgicos Cardíacos Tipo de estudo: Clinical_trials Limite: Animals / Humans Idioma: En Revista: J Thorac Cardiovasc Surg Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google